AI Article Synopsis
- The study aimed to compare nailfold capillaroscopy (NFC) findings and lung function between patients with Mixed Connective Tissue Disease associated Interstitial Lung Disease (MCTD-ILD) and those with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).
- The results indicated that significant capillaroscopic changes were more common in SSc-ILD patients (92%) compared to MCTD-ILD patients (72.3%), with SSc-ILD patients also showing greater lung function restrictions.
- The findings suggest that NFC can effectively identify lung damage severity, as more severe capillary abnormalities correlate with worse lung function in these conditions.
Article Abstract
Objective: To differentiate the nailfold capillaroscopy (NFC) findings in patients with MCTD-ILD and SSc-ILD and correlate the NFC changes and lung functions among them.
Methods: In this observational study from Oct 2020 to Oct 2022, 27 patients with MCTD-ILD and 27 patients with SSc-ILD were included. NFC was performed using Jiangsu Jiahua, JH 1004, China. Statistical analysis was conducted using IBM SPSS software, version 26, and tests including Mann-Whitney U-test, student t-test, chi-square test, or Fisher's exact test were used to compare between groups.
Results: In this study, major capillaroscopic changes were more frequent in SSc-ILD group (92%) than in MCTD-ILD group (72.3%), with normal capillaries seen in 7.4% of MCTD-ILD cases. The mean FVC was higher in SSc-ILD group compared to MCTD-ILD group, and patients with capillary loss had a lower mean FVC. Loss of capillaries was more frequent in SSc-ILD group, while dilated capillaries were predominantly observed in MCTD-ILD group. A significant association was found between the severity of restriction in spirometry and NFC.
Conclusion: There is an important role for NFC in detecting the severity of lung involvement, as the grading of restrictive severity in spirometry is strongly associated with capillaroscopic abnormalities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350414 | PMC |
| http://dx.doi.org/10.31138/mjr.260423.cnv | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial.
Rheumatology (Oxford)
December 2024
Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Objectives: Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD.
Methods: A post-hoc analysis was performed on prospective data from 48 patients with SSc-ILD in the double-blind, randomized, placebo-controlled DESIRES trial.
Quantitative F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis.
Arthritis Res Ther
December 2024
Department of Rheumatology and Clinical Immunology, Amsterdam UMC, Meibergdreef 9, Room G7-126, Amsterdam, 1105 AZ, the Netherlands.
Background: This study aimed to assess the quantitative uptake of F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD, F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters.
Methods: A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc.
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease (ILD) with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial.
Respir Med Res
November 2024
INSERM CIC1415, CHRU Tours, Université de Tours, Université de Nantes, INSERM, SPHERE, U1246, Tours, France.
Introduction: Progressive interstitial lung diseases (ILDs) are rare but severe diseases, with high mortality and morbidity, with no effective pharmacological treatment allowing for long-term remission, and therefore no clear therapeutic recommendations. Several ILDs present inflammatory components (ILDic), which may justify the use of anti-inflammatory and immunosuppressive drugs, as first-step therapy. Except for systemic sclerosis (SSc)-ILD and sarcoidosis, the evidence in favor of this approach is very weak.
View Article and Find Full Text PDFCharacterisation of incident interstitial lung disease in late systemic sclerosis.
Arthritis Rheumatol
November 2024
Department of Medicine, Division of Rheumatology, McGill University, Montreal, Canada.
Objective: Interstitial lung disease (ILD) is a common and potentially lethal complication of systemic sclerosis (SSc). Screening by HRCT is recommended in all patients with risk factors, including early disease. Little is known on late presentations of ILD.
View Article and Find Full Text PDFFAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease.
Rheumatology (Oxford)
October 2024
Division of Rheumatology, Department of Medicine, University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
Article Synopsis
- * Researchers conducted a cross-sectional analysis involving 489 SSc-ILD patients, classifying their HRCTs to determine the presence of UIP.
- * Results showed that while MUC5B was not linked to UIP patterns, the FAM13A gene was associated with an increased likelihood of definite UIP in these patients, suggesting different genetic influences compared to idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-related ILD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!